Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

NCT06996080 is registered in ClinicalTrials.gov with Kodiak Sciences Inc as lead sponsor.

NCT NCT06996080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06996080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
Lead sponsor
Kodiak Sciences Inc
Phase
Phase 3
Overall status
Recruiting
Start date
July 16, 2025
Completion date
August 31, 2027
Enrollment
300 (estimated)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

macular edema secondary to inflammation